Neoplastic Blood Disorder
Name
Institution Affiliation
Date
Question 1
The Author of the article is Elli Papaemmanuil, Ph.D., Moritz Gerstung, Ph.D., Lars Bullinger, M.D., et al., It was published June 9th 2016. The title of this article is Genomic Classification and Prognosis in Acute Myeloid Leukemia. The journal is The New England Journal of Medicine.
Question 2
This paper is mainly on understanding how genetic diversities have defined pathophysiology of acute myeloid Leukemia genomic groups and how relevant it is to the clinical outcomes when it comes to treatment and identification of the medication (Welch, Petti, Miller, et al.,2016). The research is based on the census that was conducted on genes that are mutated on acute myeloid leukaemia. The research was carried out on driver mutations that took place through the 111 cancer genes that contain cytogenetic and clinical data, and they found out that they should conduct the research-based in a different phenomenon that will help them cover the outreach.
The purpose of the research is to classify on how people get contaminated on the disease and the manner it should be handled. The paper shows how the organizations handle the situation on the patients and the manner they should treat them. The research shows how the world health organization has classified the molecular groups in the adult and how the genes undergo fusions, mutations and how they affect human beings (De Kouchkovsky, & Abdul-Hay,2016). The theoretical implication that is used in this paper is mainly on genes mutation how they happen co-currently to result in the disorder that will affect patients. The program implementation that is considered through this paper is how the disorder would be controlled so that people can not suffer more on the Leukemia through the mutations. Additionally, the paper is meant to enlighten the clinical groups that Leukemia can be controlled by suppressing the mutations.
Question 3
The literature review was drawn from the discipline of mutation on who genomic classifications and prognosis could make the condition to have a serious effect on human beings if they are not controlled at early stages. The literature mainly indicates how the clinical groups should handle the situation and implement a mechanism that would help control mutation activities that result in the Leukemia.
Question 4
The article identified the gaps on the topic that was laid for the discussion where driver landscape is in acute myeloid Leukemia revealed different molecular groups that showed the evolution of the myeloid Leukemia that the disease was to be classified that got the information on the disease stratification (Döhner, Weisdorf & Bloomfield,2015). The issues and the purpose of the research were solved through the analysis of the literature. The issues that were identified involve many mutations that take place through the cell divisions; this make the multiplication of the cells leading to Leukemia. Additionally, the genetic organizations of the cells mainly interfere with the mutation process that results to failure of cell division, leading to the acute leukaemia effect. The purpose of the paper was identified through the literature review and the theory of mutation that helped in the classification of the cell division and the manner they take place.
Question 5
The paper used the design of quantitative research where they conducted a census on people, and they collected samples of people who are suffering from the mutation. The research design helps then Author to have more details over the work that is being researched on. The paper used study participants and treatment oversight that helped the patients to be part of the research through their participation. There was the use of genetic studies that helped the Author to have content on how patients would receive induction chemotherapy and the reactions that are associated with the treatment. Additionally, the paper used a statistical analysis method that helped them to have numbers of the infected people and have an idea on how many people are likely to get affected over a period of time. The data that was collected was also presented in graphs; this helped for better understanding and analysis of the situation.
Question 6
Yes, the article is adequate for the project.
Question 7
The findings of the project are based on the biological properties of Leukemia, thus the causative driver mutations. They found out that the driver mutations are flexible and adaptable, they evolve to reflect advances when they are treated, and they influence in the changes of the disease surveillance (Papaemmanuil, Gerstung, Bullinger, et al.,2016). They concluded that the driver landscape showed different molecular subgroups that had different paths during the evolution of the myeloid Leukemia. They ended it that, cancer develops somatically from acquired driver mutations that account in the myriad biologic and clinical complexity of the ailment.
Question 8
Implications for future study for this paper is through the bride of molecules in the clinical features of the disease: the clinical presentations and the survival of the genomic subgroups. The paper gives room for the study on how the chemotherapy reactions take place and the medications for the disorder.
Question 9
The information in this article would be applied in the nursing setup through the identification of mutations that would result in other complications that are associated with myeloid Leukemia. This information also helps the nursing setup on how they should handle the leukaemia patients and find diagnosis on them.
Question 10
Yes, I will recommend this article to other people since it’s of good knowledge on the mutation of Leukemia and how it can be controlled.
Reference
De Kouchkovsky, I., & Abdul-Hay, M. (2016). Acute Myeloid Leukemia: a comprehensive review and 2016 update. Blood cancer journal, 6(7), e441-e441.Retrieved from: https://www.nature.com/articles/bcj201650
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015). Acute myeloid Leukemia. New England Journal of Medicine, 373(12), 1136-1152.Retrieved from: https://www.nejm.org/doi/full/10.1056/NEJMra1406184
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., … & Gundem, G. (2016). Genomic classification and prognosis in acute myeloid Leukemia. New England Journal of Medicine, 374(23), 2209-2221.Retrieved from: https://www.nejm.org/doi/full/10.1056/nejmoa1516192
Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., … & Lee, Y. S. (2016). TP53 and decitabine in acute myeloid Leukemia and myelodysplastic syndromes. New England Journal of Medicine, 375(21), 2023-2036.Retrieved from: https://ashpublications.org/blood/article/125/9/1367/34220/Acute-myeloid-leukemia-ontogeny-is-defined-by